Market Closed -
Nasdaq
16:00:00 2024-05-01 EDT
5-day change
1st Jan Change
4.68
USD
+25.13%
+10.38%
+89.47%
Sales 2024 *
-
Sales 2025 *
-
Capitalization
330M
453M
Net income 2024 *
-168M
-231M
Net income 2025 *
-193M
-265M
EV / Sales 2024 *
-
Net cash position
2024
*
208M
285M
Net cash position
2025
*
339M
465M
EV / Sales 2025 *
-
P/E ratio 2024 *
-1.67
x
P/E ratio 2025 *
-1.68
x
Employees
80
Yield 2024 *
-
Yield 2025 *
-
Free-Float
96.79%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Ventyx Biosciences, Inc. Announces Resignation of Christopher Krueger as Chief Business Officer, Effective on April 15, 2024
04-05
CI
Transcript : Ventyx Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 10:45 AM
03-14
Canaccord Genuity Trims Price Target on Ventyx Biosciences to $15 From $16, Maintains Buy Rating
03-13
MT
North American Morning Briefing : Stock Futures -2-
03-13
DJ
Ventyx Biosciences Shares Rise After Oppenheimer, Wells Fargo Upgrades
03-12
MT
Oppenheimer Upgrades Ventyx Biosciences to Outperform From Perform, $12 Price Target
03-12
MT
Wells Fargo Upgrades Ventyx Biosciences to Overweight From Equal Weight, Raises Price Target to $16 From $7
03-12
MT
Canaccord Genuity Adjusts Ventyx Biosciences' Price Target to $16 From $20, Maintains Buy Rating
03-11
MT
Transcript : Ventyx Biosciences, Inc. - Special Call
03-11
Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
03-11
CI
Ventyx Biosciences, Inc. announced that it expects to receive $100.0073 million in funding
03-05
CI
Lifesci Capital Upgrades Ventyx Biosciences to Outperform From Market Perform, $5 Price Target
02-28
MT
Ventyx Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
02-27
CI
Ventyx Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
02-27
CI
Wells Fargo Cuts Ventyx Biosciences Price Target to $3 From $8, Maintains Equal Weight Rating
12-19
MT
More news
VTYX DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX
04-30
PR
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)
04-29
BU
VTYX DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX
04-29
PR
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTYX
04-28
PR
The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
04-26
PR
More press releases
1 day +25.13%
1 week +10.38%
Current month +25.13%
1 month -16.28%
3 months +108.93%
6 months -67.59%
Current year +89.47%
More quotes
Managers
Title Age Since
Founder
68
18-10-31
Director of Finance/CFO
49
21-04-30
Chief Tech/Sci/R&D Officer
65
18-12-31
Members of the board
Title Age Since
Director/Board Member
69
18-10-31
Director/Board Member
61
23-01-10
Chairman
53
21-04-30
More insiders
Date
Price
Change
Volume
24-05-01
4.68
+25.13%
2,272,501
24-04-30
3.74
-2.48%
2,856,835
24-04-29
3.835
-2.42%
947,340
24-04-26
3.93
-3.20%
529,730
24-04-25
4.06
-4.25%
586,706
Delayed Quote
Nasdaq, May 01, 2024 at 04:00 pm
More quotes
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Companyâs pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
More about the company
Last Close Price
4.68
USD
Average target price
10.8
USD
Spread / Average Target
+130.77%
Consensus
1st Jan change
Capi.
+89.47% 264M -1.17% 102B +2.87% 96.09B +2.13% 22.28B -14.77% 21.4B -8.79% 18.14B -39.98% 17.02B -13.21% 16.09B +8.55% 13.83B +35.75% 11.97B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1